In addition, Rostami et al. provided evidence indicating that patients with BM resulting from HER2-positive BC had an extended mean survival following treatment with trastuzumab, reporting a longer mean survival of 17.5 months compared to 11 months for untreated patients. The gene discussed is ERBB2; the disease is breast cancer.